X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to support Phase II clinical development of BioAge’s lead compound BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: BGE-105
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sofinnova Investments
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing February 13, 2024
Details:
As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.
Lead Product(s): Azelaprag,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: BGE-105
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2023
Details:
BGE-105 is a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. Phase 1b trial data released to date demonstrate that in healthy volunteers 65 and older on 10-day strict bed rest.
Lead Product(s): BGE-105
Therapeutic Area: Musculoskeletal Product Name: BGE-105
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
BGE-105 is a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. Apelin, the natural ligand of APJ, is secreted by skeletal muscle in response to exercise and regulates multiple aspects of muscle metabolism, growth, and repair.
Lead Product(s): BGE-105
Therapeutic Area: Musculoskeletal Product Name: BGE-105
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
Family of NLRP3 inhibitors is differentiated by novel structure, central nervous system penetration, and potential for improved safety and efficacy,for neurodegenerative and neurosensory disorders associated with aging.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
The inhibitors, BioAge’s first proprietary compounds, were created by leveraging the Company’s unique platform and in-house drug development expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
In aged mouse models, a highly selective and potent small-molecule agonist of the apelin receptor APJ, BGE-105 substantially rescued muscle atrophy due to limb immobilization, prevented loss of muscle function with age, and induced biomarkers of muscle regeneration.
Lead Product(s): BGE-105
Therapeutic Area: Musculoskeletal Product Name: BGE-105
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Multi-center, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of daily oral BGE-175 for up to 14 days.
Lead Product(s): Asapiprant
Therapeutic Area: Infections and Infectious Diseases Product Name: BGE-175
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
In this randomized, placebo-controlled, double-blind, multi-center Phase 2a trial, 160 UAA patients 65 years or older will receive daily oral doses of BGE-117 or placebo (80 patients in each group) for 3 months.
Lead Product(s): BGE-117
Therapeutic Area: Hematology Product Name: BGE-117
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
Details:
With this agreement, Shionogi grants BioAge exclusive U.S. and European rights to develop and commercialize BGE-175 for COVID-19 treatment. In addition, Shionogi grants BioAge exclusive rights to negotiate a license for additional indications.
Lead Product(s): Asapiprant
Therapeutic Area: Infections and Infectious Diseases Product Name: BGE-175
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Shionogi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
